The Venture Codex Logo

The Venture Codex

Bukwang Pharmaceutical

7, Sangdo-ro, Dongjak-gu, Seoul, Seoul-t'ukpyolsi, 06955, South Korea

Overview

Pharmaceutical company focused on improving global health with medications.

Founded

1960

Deals ยท 12mo

0

Links

WebsiteLinkedIn

Stage focus

Series A
Series B

Geographic focus

Israel
United States

Sector focus

Manufacturing
Medical Device

Investment portfolio

4rounds
NAMEDATESIZE
ImmPACT Bio
Jan 2022Led
$111 MSeries B
ImmPACT Bio
Aug 2020Participated
$18 MSeries A
Protekt Therapeutics
Nov 2019Led
$4 MOther Equity
Acer Therapeutics
May 2016Participated
$8 MSeries B
ImmPACT Bio
Jan 2022Led
$111 MSeries B
ImmPACT Bio
Aug 2020Participated
$18 MSeries A
Protekt Therapeutics
Nov 2019Led
$4 MOther Equity
Acer Therapeutics
May 2016Participated
$8 MSeries B
4
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Bukwang Pharmaceutical: 4 funding rounds are recorded in the selected participation categories.All available history.
Bukwang Pharmaceutical: 4 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A01
Series B11
Other Equity10

Monthly Deal Activity

Bukwang Pharmaceutical: 4 deals are recorded across 126 months.All available history.
Bukwang Pharmaceutical: 4 deals are recorded across 126 months. All available history
MonthDeals
May '161
Jun '160
Jul '160
Aug '160
Sep '160
Oct '160
Nov '160
Dec '160
Jan '170
Feb '170
Mar '170
Apr '170
May '170
Jun '170
Jul '170
Aug '170
Sep '170
Oct '170
Nov '170
Dec '170
Jan '180
Feb '180
Mar '180
Apr '180
May '180
Jun '180
Jul '180
Aug '180
Sep '180
Oct '180
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '190
Nov '191
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '201
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '221
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Bukwang Pharmaceutical: Health & Life Sciences is the largest displayed sector by deal count (4 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Bukwang Pharmaceutical: Health & Life Sciences is the largest displayed sector by deal count (4 deals). All available history
SectorDeals
Health & Life Sciences4

Deal Size Distribution

Bukwang Pharmaceutical: 4 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Bukwang Pharmaceutical: 4 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M1
$5M-$10M1
$10M-$25M1
$25M-$50M0
$50M-$100M0
$100M-$250M1
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Bukwang Pharmaceutical: United States has the largest recorded deal count among the displayed regions (3 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

Bukwang Pharmaceutical: United States has the largest recorded deal count among the displayed regions (3 deals). All available history
RegionDeals
United States3
Israel1
Bukwang Pharmaceutical: 14 co-investors are shown, with OrbiMed sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Bukwang Pharmaceutical: 14 co-investors are shown, with OrbiMed sharing 3 recorded deals. All available history
Co-investorShared deals
OrbiMed3
RM Global Partners3
Johnson & Johnson Innovation2
Novartis2
Takeda Ventures2
Decheng Capital1
Fonds de solidarit FTQ1
Foresite Capital1
FutuRx1
Hayan Health Networks1
JVC Investment Partners1
Surveyor Capital1
TVM Capital1
venBio Partners1

Investment Strategy

Bukwang Pharmaceutical: Led accounts for 50% and participating for 50% of round participation.All available history.
Bukwang Pharmaceutical: Led accounts for 50% and participating for 50% of round participation. All available history
CategoryDeals (count)Share (%)
Led250%
Participating250%
Bukwang Pharmaceutical: Single-lead accounts for 0% and co-led for 100% of lead dynamics.All available history.
Bukwang Pharmaceutical: Single-lead accounts for 0% and co-led for 100% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led2100%

Team

Hee-Won Yoo

Co-President, Co-Chief Executive Officer & Director

Sang-Hoon Kim

Co-President, Chief Strategy Officer & Director